Ab­b­Vie, Gen­mab land FDA OK for CD3xCD20 bis­pe­cif­ic, catch­ing up with Roche

Ab­b­Vie and Gen­mab have land­ed an ac­cel­er­at­ed FDA ap­proval for their CD3xCD20 bis­pe­cif­ic, adding an op­tion for pa­tients with re­lapsed/re­frac­to­ry large B cell lym­phoma.

While the com­pa­nies are com­ing in sec­ond af­ter Roche’s Genen­tech — whose bis­pe­cif­ic mo­sune­tuzum­ab was ap­proved as Lun­sumio in De­cem­ber — they note that their drug, ep­cori­ta­m­ab, is the first sub­cu­ta­neous bis­pe­cif­ic an­ti­body ap­proved as a third-line treat­ment of this can­cer type. It will be mar­ket­ed as Ep­kin­ly. The treat­ment has a month­ly list price of $37,500, ac­cord­ing to a spokesper­son, who not­ed that the av­er­age du­ra­tion of ther­a­py is about nine months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER